Belluscura cleared to launch POC

LONDON — Tekcapital has announced that its portfolio company Belluscura has been granted 510(k) clearance and marketing authorization by the U.S. Food and Drug Administration for its X-PLO2R portable oxygen concentrator. "We are excited to see that the FDA has cleared the X-PLO2R device for sale, as Tekcapital and Belluscura believe it could be helpful to patients during the COVID-19 pandemic, and for many of the 250 million people worldwide suffering from COPD," said Clifford Gross, PhD, executive chairman of Tekcapital. Belluscura developed the POC with its research partner Separation Design Group, an "oxygen enrichment research laboratory." Belluscura expects to commercially launch the X-PLO2R, which delivers up to 95% pure oxygen to patients 24 hours a day, 7 days a week, and weighs 3.25 pounds, this year. Tekcapital owns about 17.85 of Belluscura.